Methylnaltrexone: Peripherally Acting μ-Opioid Receptor Antagonist
Tanya J. Uritsky, PharmD, BCPS, CPE
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Author’s disclosures of conflicts of interest are found at the end of this article.
Tanya J. Uritsky, PharmD, BCPS, CPE, Hospital of the University of Pennsylvania, 3400 Spruce Street, Ground Floor Rhoads Building, Philadelph-ia, PA 19104.
J Adv Pract Oncol 2019;10(1):62–67 |
© 2019 Harborside™
Opioid-induced constipation (OIC) is a common adverse effect associated with opioid therapy, with many patients never developing tolerance to this effect. There are many traditional laxatives available to help patients combat this symptom, yet OIC may not reliably respond to conventional treatment. Peripherally acting μ-opioid receptor antagonists (PAMORAs) have a place in the treatment of refractory OIC, when traditional laxatives have not resulted in effective laxation. There are a number of PAMORAs now available, and methylnaltrexone is the only PAMORA indicated for the treatment of OIC in adults with advanced illness, as well as for patients with chronic noncancer pain, including patients with chronic pain related to prior cancer treatment who do not require frequent opioid escalation. Advanced practitioners need to have an understanding of how and when to best use these medications for the different indications in patients with advanced illness or chronic noncancer-related pain.
For access to the full length article, please sign in